SYSTEN Conti patch mat 50/170 sach 24 pce

7680547150210 CH-54715 G03FA01 07.08.6.
SYSTEN Conti patch mat 50/170 sach 24 pce
SYSTEN Conti patch mat 50/170 sach 24 pce
SYSTEN Conti patch mat 50/170 sach 24 pce
1 / 3
google

Details

Product number
5471501
CPT
-
Packaging group
24
Unit
Pflaster
Composition
estradiolum 3.1 mg ut estradiolum hemihydricum 3.2 mg, norethisteroni acetas 11.2 mg, guari gummi, isooctyl acrylate/vinyl acetate copolymer, matériel du support: poly(ethylenis terephthalas), ad praeparationem pro 16 cm² cum liberatione 50 µg/24 h et 170 µg/24 h.

Articles (1)

Systen Conti, patch transdermique
Pflaster
24
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
15/09/2025
Patient information leaflet
Français
15/09/2025
Patient information leaflet
Italien
15/09/2025
Professional SmPC
Allemand
15/09/2025
Professional SmPC
Français
15/09/2025
Professional SmPC
Italien
15/09/2025

Detailed composition

Substance Quantity Type Category
(N/A)
3.1 MG Substance Wirkstoff (Principe actif)
(N/A)
3.2 MG Substance WIZUS
(N/A)
11.2 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 50.45
Specialties list
Yes
Generic
No
SL addition date: 15/04/2000

Authorization holder

Labatec Pharma SA

1217 Meyrin

Authorization information

Swissmedic authorization number
54715
Drug name
Systen Conti, patch transdermique
Galenic form
TRAP
ATC Code
G03FA01
Authorization status
Z
Dispensation category
B
First authorization
24/12/1998
Authorization expiration date
31/12/9999
IT number
07.08.6.
Domain
Human medicine
Field of application
Oestrogen-Gestagen-Substitutionstherapie nach der Menopause

Packaging details

Description (FR)
SYSTEN Conti patch mat 50/170 sach 24 pce
Description (DE)
SYSTEN Conti Matrixpfl 50/170 Btl 24 Stk
Market launch
24/12/1998
Narcotic (BTM)
No

Other packaging sizes

SYSTEN Conti patch mat 50/170 sach 8 pce
8 PFLA
View